Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo has reported that a federal court has granted summary judgment in its favor in patent litigation involving Guaifenesin extended-release tablets, 600 mg, a generic version of Mucinex tablets.
Subscribe to our email newsletter
Perrigo had been sued by Adams Respiratory Therapeutics, a subsidiary of Reckitt Benckiser Group, the new drug application holder and patent owner. The US District Court for the Western District of Michigan ruled that Perrigo does not infringe the patent in the suit. Perrigo’s ANDA is awaiting FDA approval.
The company said that Mucinex (guaifenesin extended-release tablets, 600 mg) an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $162m through food, drug and mass merchandisers for the 12 months ended January 2010, as measured by ACNielsen.
Joseph Papa, chairman and CEO of Perrigo, said: “This is another example of Perrigo’s investment and commitment to bringing new store brand products to the market. This will be an important new store brand product addition in the cough/cold category to our retail and wholesale customers while providing significant savings for the US consumer. Perrigo is working every day to make quality healthcare more affordable.”
The US-based Perrigo is a healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products.